Effect of Subcutaneous Tocilizumab on Mortality in Patients With COVID-19: A Meta-analysis of Retrospective Cohort Studies.
作者信息
Peng Tzu Rong, Wu Ta Wei, Wu An Jan
机构信息
Department of Pharmacy, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical, Foundation, New Taipei City, Republic of China.
School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei City, Republic of China.
出版信息
Am J Ther. 2021 Jul 27;28(5):e584-e585. doi: 10.1097/MJT.0000000000001434.
Abstract
摘要
相似文献
1
Effect of Subcutaneous Tocilizumab on Mortality in Patients With COVID-19: A Meta-analysis of Retrospective Cohort Studies.
Am J Ther. 2021 Jul 27;28(5):e584-e585. doi: 10.1097/MJT.0000000000001434.
2
Tocilizumab administration in patients with SARS-CoV-2 infection: Subcutaneous injection vs intravenous infusion.
J Med Virol. 2021 Jan;93(1):69-70. doi: 10.1002/jmv.26124. Epub 2020 Jun 19.
3
Tocilizumab prescribing criteria for COVID-19 patients.
Hum Vaccin Immunother. 2021 Apr 3;17(4):1128. doi: 10.1080/21645515.2020.1822137. Epub 2020 Oct 20.
4
Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia.
J Med Virol. 2021 Jan;93(1):32-34. doi: 10.1002/jmv.26016. Epub 2020 Sep 30.
5
The effect of tocilizumab, anakinra and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: A prospective cohort study with multivariate analysis of factors affecting the antibody response.
Int J Infect Dis. 2021 Apr;105:756-762. doi: 10.1016/j.ijid.2021.03.031. Epub 2021 Mar 15.
6
Effect of Tocilizumab in Mortality among Patients with Severe and Critical Covid-19: Experience in a Third-Level Medical Center.
Rev Invest Clin. 2022 Jan 3;74(1):40-50. doi: 10.24875/RIC.21000404.
7
Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis.
Respirology. 2021 Nov;26(11):1027-1040. doi: 10.1111/resp.14152. Epub 2021 Oct 3.
8
Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study.
J Clin Pharm Ther. 2021 Apr;46(2):440-446. doi: 10.1111/jcpt.13303. Epub 2020 Oct 24.
9
Tocilizumab in COVID-19: The Cerrahpaşa-PREDICT score.
J Infect Chemother. 2021 Sep;27(9):1329-1335. doi: 10.1016/j.jiac.2021.05.007. Epub 2021 May 12.
10
In patients hospitalized for COVID-19, tocilizumab reduces mortality at 28 d.
Ann Intern Med. 2021 Nov;174(11):JC125. doi: 10.7326/ACPJ202111160-125. Epub 2021 Nov 2.
本文引用的文献
1
Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies.
Int J Infect Dis. 2020 Dec;101:59-64. doi: 10.1016/j.ijid.2020.09.1447. Epub 2020 Sep 28.
2
Tocilizumab in patients with severe COVID-19: a retrospective cohort study.
Lancet Rheumatol. 2020 Aug;2(8):e474-e484. doi: 10.1016/S2665-9913(20)30173-9. Epub 2020 Jun 24.
3
Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia.
J Med Virol. 2021 Jan;93(1):32-34. doi: 10.1002/jmv.26016. Epub 2020 Sep 30.
Zotero 插件